Clinical Trials Arena on MSN
Agomab’s ALK5 inhibitor to advance to Phase IIb in Crohn’s disease
Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...
ScienceAlert on MSN
A Crucial Genetic Mutation Behind Crohn's Disease Has Finally Been Revealed
Mutations in a gene associated with Crohn's disease have been found to rob critical immune cells of their ability to switch ...
Proactive care and early treatment help prevent serious IBD complications and improve patients’ quality of life.
A family says their car was totaled in a hit-and-run, and police said the person who struck them was a high-ranking member of ...
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...
Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a ...
Objectives Disease activity assessment is important for Crohn’s disease (CD) management, since it involves the initial and subsequent therapeutic schedule. The purpose of this study is to identify a ...
Auburn kicker Alex McPherson was diagnosed with ulcerative colitis in April 2024, after suffering from symptoms that included significant weight loss. After Auburn's 2024 season, McPherson underwent a ...
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing ...
*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results